A tiny Long Island biotechnology startup in a global race to develop a COVID-19 vaccine has rolled out plans for a human trial.The Phase 1 trial using about 50 paid young adult volunteers will evaluate the safety of the Codagenix Inc. vaccine and will be conducted in London by a unit of Dublin-based Open Orphan plc.
Codagenix Inc.’s vaccine is made from a live, but attenuated — or weakened — version of the whole virus that is re-engineered to slow its ability to make copies of itself.That differs from nearly every other vaccine candidate of the 169 cataloged by the World Health Organization.Other than Codagenix and two other developers, according to WHO, all use dead virus, some of the virus’ genetic material or a section of the virus such as the spike protein.
13 States Make Contact Tracing Data Public
The data states are gathering includes how many contacts are reached and how quickly and where people were exposed — whether it was out in public or at home. The few states analyzing and sharing this data represent “a good start,” says Crystal Watson, senior scholar at the Center for Health Security who collaborated with NPR on the survey. “It’s a little bit scattershot right now.” What’s needed, she says, is for states to share contact tracing data “more, more widely and more consistently.”
She acknowledges that states are limited by a lack of resources. “Health departments are really stretched to the limit right now, and it’s not a trivial thing to put together the data infrastructure to report [this data] publicly,” Watson says. Some federal guidance on “what states should be aiming to report publicly” could be really helpful, she says.In the meantime, here are six places already making some of the data gleaned from their contact tracing efforts public, which illustrate how useful this information can be.